NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

So agree that changes are possible, but do carry risks.

exwannabe,

comments from Fraunhofer IZI sound good.

In order to manufacture DCVax®-L for each individual patient, tumor tissue and a blood product first had to be taken from the patient before the cell-based therapeutic agent could then be manufactured in a complex, multi-stage process.
The number of patients that had to be recruited for the trial from a statistical perspective was reached back in 2015, marking the successful completion of the manufacturing and testing activities at Fraunhofer IZI. https://www.izi.fraunhofer.de/content/dam/izi/en/documents/Publications/Annual_Report_IZI_2017.pdf